Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy G. Chadwick Sells 1,383 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Kymera Therapeutics Price Performance

NASDAQ KYMR traded down $1.18 during trading hours on Monday, hitting $30.17. The company had a trading volume of 982,064 shares, compared to its average volume of 578,939. The firm’s 50 day moving average is $38.81 and its 200 day moving average is $43.66. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -12.89 and a beta of 2.18. Kymera Therapeutics, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Kymera Therapeutics during the 4th quarter valued at $4,610,000. GF Fund Management CO. LTD. purchased a new position in Kymera Therapeutics in the 4th quarter valued at about $55,000. Woodline Partners LP grew its stake in shares of Kymera Therapeutics by 2.3% during the fourth quarter. Woodline Partners LP now owns 537,428 shares of the company’s stock valued at $21,621,000 after acquiring an additional 12,334 shares in the last quarter. Vident Advisory LLC purchased a new stake in shares of Kymera Therapeutics during the fourth quarter worth about $236,000. Finally, State of Wyoming purchased a new stake in shares of Kymera Therapeutics during the fourth quarter worth about $45,000.

Analysts Set New Price Targets

A number of research firms have recently commented on KYMR. HC Wainwright upped their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday. Stephens reaffirmed an “overweight” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Morgan Stanley lifted their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday, November 6th. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $38.00 to $57.00 in a report on Monday, December 2nd. Finally, BMO Capital Markets began coverage on Kymera Therapeutics in a research report on Friday, December 6th. They issued a “market perform” rating and a $55.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.69.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.